• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
Mad Hedge Fund Trader

November 25 Biweekly Strategy Webinar Q&A

Diary, Newsletter

Below please find subscribers’ Q&A for the November 25 Mad Hedge Fund Trader Global Strategy Webinar broadcast from Silicon Valley, CA with my guest and co-host Bill Davis.

 Q: Is gold (GLD) still a hold?

A: Long term yes; short term no. Short term, cash is being drained out of gold in order to buy Bitcoin, just like silver. And once Bitcoin peaks, which could be today or tomorrow when it hits 20,000, then you could get a round of profit-taking and a nice little pop in gold. So, it's basically moving totally counter-cyclically to Bitcoin and the other cryptocurrencies right now.

(Note: since this webinar, Bitcoin has crashed by $3,000)

Q: A competitor of yours claims that asymptomatic transmission of COVID does not occur.

A: I would bet money that person does not have a medical degree. Asymptomatic transmission occurs in almost all diseases, so why COVID would be an exception is beyond me. I suggest that somebody is trying to sell newsletters at your expense with zero knowledge about the topic. Ask him to kiss a Covid victim. This is common in my industry where 99% of the people are crooks. This is also an example of the vast amounts of information that have been spread during an election year.

Q: Will you take a vaccine when it’s out or will you let others try it first?

A: Actually, by the time the public gets the vaccine, more than a million people will have already tried it, so I think it will be fairly safe. I am probably already the most vaccinated person on the planet; I've had flu shots every year for 40 years, so I will happily try it out. At my age, I have little to lose. And I would like to travel again, and that’s going to be a requirement for international travel. I am worried there could be long term side effects that we’ve seen with other drugs in the past, like all future children being born without arms and legs, which is what happened in the 1950s with Thalidomide.

Q: If the Senate flips to the Democrats, how do you see it affecting the market?

A: It doesn’t really affect the market overall; what it will do is affect sector reallocation. Solar, alternative energy and ESG companies do a lot better in A Democratic Senate, and energy oil companies do a lot worse. All you do is short the losers and buy the winners; it really makes no difference who wins. Most of the big conflicts over issues these days are social ones that don’t affect the market.

Q: Where do you see Tesla (TSLA) by the end of the year?

A: Well, this morning, it’s at an all-time high of $565. It looks like it wants to take a run at $600, and then we will be up 50% from where the news was announced that it was joining the S&P 500. That seems to me like a heck of a move on no real fundamental news. During this news, the market completely ignores a Model X recall and a Model Y pan from Consumer Reports. I would be inclined to take profits there or at least roll the strikes up on my options positions.

Q: What’s a good stock to play a commodity recovery?

A: You can’t do any better than Freeport-McMoRan (FCX), which I’ve been following for almost 50 years since I covered it for the Australian Financial Review newspapers.

Q: Will Salesforce (CRM) hold?

A: Yes, it’s just a matter of time before we break out to substantial new highs, and this is a stock that could double next year.

Q: What brokers do you suggest?

A: I would pick tastytrade, owned by my friend Tom Sosnoff who will be speaking at the Mad Hedge Traders & Investors Summit next week and will be answering all your questions. Click here for their site.  To register for the summit, click here.

Q: Is CVS (CVS) a good buy?

A: I would say yes; a billion Covid-19 vaccine doses will need to be distributed next year. You can't do that without all the drug companies participating big time.

Q: Does Trump have a chance to win in his lawsuits?

A: It’s more likely that I will be elected the next Miss America; so, I wouldn’t place any bets on that. Some 30 consecutive Republican judges ruling against him does not augur well for his future.

Q: Would you buy any LEAPS here (Long Term Equity Participation Securities)?

A: Only in special one-off situations in the domestic stocks that haven’t moved in ten years. There are a lot of those out there now that I have been recommending. Those are all fertile territory for LEAPs, especially going out 2 years where you get the maximum bang for the buck and a 1,000% return. Don’t touch LEAPs in technology stocks here, and don’t touch Tesla in LEAPs.

Q: What’s your outlook on Southwest Air (LUV)?

A: I like it; it’s one of the healthiest domestic airlines most likely to come back.

Q: Are you going to update your long-term portfolio?

A: Yes, but I only update it twice a year and my next turn is on January 22. If you bought the last update on July 22, you made a fortune getting into Freeport McMoRan at $12 (it’s now $23), CRISPER Therapeutics at $80 (CRSP) (it’s now $110), and Square (SQ) at $110 (the current is $212). You can find it by logging into www.madhedgefundtrader.com, going to My Account, clicking on Global Trading Dispatch, on the drop-down menu, click on the Long-Term Portfolio tab and then clicking on the red tab for the Long-Term Portfolio. That lets you download an excel spreadsheet.

Q: Do you have any LEAPS to suggest now?

A: I only put out portfolios of LEAPS at giant market bottoms like we had in March. Then I put out lists and lists of LEAPS. At all-time highs, it’s not good LEAPS territory, except for specific names. So, if you want to get involved in that on a regular basis, I suggest you sign up for our Mad Hedge Concierge Service. There they are making millions of dollars a week right now.

Q: Where does the US dollar (UUP) go from here?

A: Straight down; the outlook for the buck couldn't be worse. I would be selling short the US dollar like crazy right now except that there are much better trades in US equities.

Q: Just to be clear, there’s no voter fraud?

A: There’s probably never been an election in US history without voter fraud on all sides; it’s just a question of who’s better at it. In the 1948 Texas Democratic Party runoff, back when the party owned Texas, Lyndon Johnson won by 87 votes out of 988,295 cast. It was later found that in five Hispanic-dominated counties that bordered Mexico, everyone had voted 100% for Johnson ….in alphabetical order. Johnson then took the seat with a 66% margin and went on to dominate the US Senate. I remember in the 1960 election, all the military absentee votes were sent flying around in circles over the Atlantic so Kennedy would win; that’s a story that’s been out there for a long time.

Q: You said stay away from other EVs except for Tesla?

A: A few have gone crazy this week, but that doesn’t mean they can actually make a car. So, you might get lucky on a quick trade on some of these, but long term, I don’t think any of the other non-Tesla EV companies are going to make it except for General Motors, which is plowing $27 billion into the sector. Even if (GM) may be able to put out a lot of cars, but they won’t be able to make very much money at it because they’re nowhere near the neighborhood of Tesla with the software where all the money is made.

Q: As the dollar gets weaker, will you expand your international stock picks?

A: Yes, we put out the first one in a long time, Ali Baba (BABA), on Monday, and we’ll be adding to that a bunch. I think the dollar could be weak for 5 or 10 years, a lot like it was in the 1970s.

Q: What’s your outlook for silver (SLV)?

A: Same as for gold (GLD). Quiet for the short term, double for the long term.

Q: Favorite names in biotech?

A: For that, you really need to subscribe to the biotech letter; we’re giving you two names a week there and all of them have done great. But another one might be Thermo Fisher (TMO), which seems to double every time I recommend it. It’s a great takeover target too.

Q: Is there any possibility of a 30% dip in the market (SPY) in 2021?

A: No, I don’t see more than a 10% dip in 2021. The tailwinds now are gale-force, generational, and will run for a decade.

Q: How do you sell the US dollar rally?

A: You buy all the ETFs that we cover in our foreign exchange sections. Those are the Australian dollar (FXA), the Euro (FXE), the Japanese Yen (FXY), the British pound (FXB), and the Chinese Yuan (CYB). Those are five ETFs that will do well on a weak dollar for the next several years.

Q: What about the Invesco Solar ETF TAN?

A: We have been recommending (TAN) for many years and it has done spectacularly well. I still love it long term, but it’s had one heck of a run; it’s up 300% from the March low. I think the entire country is about to have a solar explosion because the costs are now quite simply less than for oil. It’s an economic question. We are going to an all-Electric America.

Q: What do you think about LEAPS on gold?

A: It’s not really LEAPs territory yet, but on a two-year view, you’d have to do well on gold LEAPs.

Q: Is the Invesco DB US Dollar Index Bullish Fund (UUP) good to buy?

A: You should be looking to short the UUP. It’s a long dollar basket which we think will do terribly.

Good Luck and Stay Healthy.

John Thomas
CEO & Publisher
The Diary of a Mad Hedge Fund Trader

 

 

 

 

 

https://www.madhedgefundtrader.com/wp-content/uploads/2019/03/John-Thomas-2.png 304 406 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-11-27 10:02:212025-04-12 10:03:19November 25 Biweekly Strategy Webinar Q&A
Mad Hedge Fund Trader

November 25, 2020

Tech Letter



Mad Hedge Technology Letter
November 25, 2020
Fiat Lux

Featured Trade:

(A COMPANY AT THE CROSSROADS OF HEALTH CARE AND TECH)
(SDGR)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-11-25 14:04:432020-11-25 14:58:55November 25, 2020
Mad Hedge Fund Trader

A Company at the Crossroads of Healthcare Tech

Tech Letter

For those speculative tech investors, I have an early-stage tech company that could be of interest to you.

This one is a big loss-maker just like in the mold of most growth companies, but they have the stereotypical revenue growth trajectory that is prevalent in strong tech stocks.

It might be a while before this one turns a meaningful profit but this company also sits at the intersection of healthcare and software cloud computing which is an ideal place to be in the 2020s.

Investors who can absorb higher risk and volatile price action should take a flyer on Schrödinger, Inc. (SDGR) who provides a computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide.

Their most recent earnings reports offer us a brief snapshot of this burgeoning software company with software revenue underpinning top line of $22.9 million, an increase of 42% compared to the third quarter last year.

Schrödinger continues to see deeper engagement within the platform by customers, leading to robust year-over-year growth in software revenue.

They also have a talented team of scientists and software developers that continue to make significant progress in advancing the science that undergirds the computational platform.

Schrödinger recently published several papers describing advances in FEP+, including improved methods for accurately modeling binding affinities in metalloenzyme inhibitors, improved support of macrocycle design and optimization, and improved approaches to optimizing binding selectivity, which is a major way of reducing potential toxicity of drug molecules.

Schrödinger also adopted active learning workflow for structure-based hit discovery, which can screen massive libraries of compounds with greatly improved computational efficiency.

The firm has seen new drug candidates discovered in their collaborative programs progress into IND-enabling and first-in-human studies.

I believe these advancing programs represent examples of the impact of Schrödinger’s physics-based methods, not just in achieving broad exploration of chemical space, but more importantly, on the optimization of high quality development candidates, with balanced properties for clinical testing.

As an example, Morphic's MORF-057 for inflammatory bowel disease, which initiated a clinical trial in the third quarter, is one of several examples where Schrodinger Technology-enabled solutions to their health partner's preclinical design challenges.

In this case, the design of selective compounds for the integrin alpha 4 beta 7 was enabled by an important advancement to properly treat the receptor's metal centers.

Schrödinger recently reported a significant increase in the number of collaborative programs that had reached the latest stages of drug discovery.

I expect to see many of the collaboration programs and lead optimization into preclinical development over the next year.

What about the internal pipeline?

Schrödinger launched five oncology programs targeting solid tumors and hematological malignancies.

The preclinical data packages assembled to date include mechanistic validation and anti-tumor activity data.

I believe, based on the data generated to date, that each of these assets could have monotherapy activity in specific populations, as well as utility, in combination with other approved and late-stage oncology products.

Looking forward, Schrödinger has also prioritized several new program opportunities, with genetic support in human cohorts and emerging pharmacology data, in oncology and immunology.

In addition to strategic hires in preclinical and early clinical development, they have also expanded the drug discovery team, adding key seasoned immunology expertise.

All of this translates into a meaningful rise in software revenue because of the increased adoption of solutions by large customers, as well as the addition of new customers.

Schrödinger continues to experience strong uptake in live design, and their enterprise solution for drug discovery.

Live design integrates discovery workflows and can be especially powerful in fully remote work environments that many of us are still experiencing.

Software gross margin was 81% this quarter, unchanged from the third quarter of 2019.

Schrödinger’s business model has not been impacted by the health pandemic, and neither is its future runway of potential revenue.

The only drag from the pandemic is on the drug discovery side, it could cause temporary delays in some programs. In any case, I do not envision a long-term impact from the public health situation on Schrödinger’s ability to execute and deliver on its strategy.

In summary, Schrödinger’s outperformance stems from its brilliant execution across its array of businesses, resulting in strong revenue growth, increasing collaboration equity value, progress in internal and collaboration programs, continued scientific advancement of in-house technology, and the successful IPO and follow-on financings that strengthen their balance sheet and provide strategic optionality.

Annual revenue still is under an annual run-rate of $100 million and as software revenue growth still displays robust plus-40% growth rates and a juicy gross margin of 81%, it’s only a matter of time before institutional investors start deploying capital in this up-and-coming tech name.

 

Schrödinger

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-11-25 14:02:302020-11-28 00:49:50A Company at the Crossroads of Healthcare Tech
Mad Hedge Fund Trader

November 25, 2020 - Quote of the Day

Tech Letter

“AI will not replace physicians. However, physicians who use AI will replace those who do not.” – Said The Mad Hedge Fund Trader John Thomas

https://www.madhedgefundtrader.com/wp-content/uploads/2020/06/john-marketplace.png 254 432 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-11-25 14:00:392020-11-25 14:57:59November 25, 2020 - Quote of the Day
Mad Hedge Fund Trader

November 25, 2020 - MDT Alert (EGAN)

MDT Alert

Today, I would like to make a recommendation on a stock purchase.

The stock is eGain Communications Corp. (EGAN).

EGAN is trading around $11.36 as I write this.

It does have monthly options, but I am not going to suggest you sell calls at this time.

I am going to suggest you buy the stock because this will be swing trade. The idea is that EGAN will follow through on the reversal it is putting in today.

Buy EGAN at the market, which is $11.36.

Based on the nominal portfolio, limit the buy in to 400 shares or 4.5% of the portfolio.

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-11-25 11:29:012020-11-25 11:29:01November 25, 2020 - MDT Alert (EGAN)
Mad Hedge Fund Trader

November 25, 2020 - MDT Pro Tips

MDT Alert

While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to a six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three-day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points. Read more

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-11-25 09:15:072020-11-25 09:15:07November 25, 2020 - MDT Pro Tips
Mad Hedge Fund Trader

November 25, 2020

Diary, Newsletter, Summary

Global Market Comments
November 25, 2020
Fiat Lux

FEATURED TRADE:

(THE MAD HEDGE TRADERS & INVESTORS SUMMIT DECEMBER 1-3),
(TESTIMONIAL)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-11-25 09:06:592020-11-25 09:49:22November 25, 2020
Mad Hedge Fund Trader

The Mad Hedge Traders & Investors Summit December 1-3

Diary, Newsletter

I’ve spent the last 50 years looking for the best traders & investors in the world. I wanted to learn from them and to hire them as well. Now you can meet some of the people I’ve found, the cream of the crop at the top of their games.

You can learn more listening to them in an hour than reading a dozen books or attending a hundred webinars.

To see what they have to say right now, all you have to do is attend the Mad Hedge Traders & Investors Summit from December 1, 2, and 3 from Tuesday to Thursday.

In it I will cover:

Dow 40,000 Here We Come!

*2021 could be the best year of the decade for stocks, with Dow 40,000 within reach, up 35%

*A Perfect Storm of positive economic conditions will trigger a massive increase in stock earnings multiples and prices

*2020 was only a short-term dip in a 20-year bull market that may have another decade to run

*Most pandemic business activities weren’t lost but deferred, leading to an explosion in spending in 2021

*Many domestic recovery stocks have barely moved in a decade and now have explosive upside potential

*”Reopening” stocks like (DIS), (BA), airlines, hotels, and cruise lines have already had huge moves but still have much to run

*2021 will be a year to be fully invested and 100% “RISK ON”

To join, just click here. It will be the best investment of time you’ve ever made. I’ll see you there. This is John Thomas signing off for now. Good luck and good trading.

https://www.madhedgefundtrader.com/wp-content/uploads/2020/05/mr-john-thomas-1-e1595422688475.png 567 450 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-11-25 09:04:122020-11-25 09:48:30The Mad Hedge Traders & Investors Summit December 1-3
Mad Hedge Fund Trader

Trade Alert - (TSLA) November 24, 2020 - SELL-TAKE PROFITS

Trade Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-11-24 15:04:212020-11-24 15:04:21Trade Alert - (TSLA) November 24, 2020 - SELL-TAKE PROFITS
Mad Hedge Fund Trader

November 24, 2020

Biotech Letter

Mad Hedge Biotech & Healthcare Letter
November 24, 2020
Fiat Lux

FEATURED TRADE:

(WATCH OUT FOR BIONTECH’S HOCKEY STICK GROWTH)
(BNTX), (PFE), (AZN), (MRNA), (JNJ), (REGN), (DNA)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-11-24 13:02:492020-11-24 14:23:35November 24, 2020
Page 2 of 16‹1234›»

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
Scroll to top